PATENT CLAIM ANALYSIS

Application Number: 16023058
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "274000"]

Abstract:
The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Claim (Index 15):
A method of treating anemia associated with cancer chemotherapy in a human which comprises administering to such human N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 94.0
- Lexical Diversity: 1.07692
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15187075', '12305675', '13667634', '14026164', '11972702']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8345354014459845
- 35 USC 102 Novelty (BERT): 0.6494344250330486
- Combined Prediction Score: 0.816025303804691
- Mean Citation Score: 520.80945
- Max Citation Score: 645.47217
- Similarity Product: 585.6807947383243

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test